# Corcept (CORT) Stock Price, News & Analysis
Canonical URL: https://biopharmsignal.com/company/CORT
## Company Profile
- Ticker: CORT
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
- Tags: Endocrinology
## Stock Data
- Close: 110.69 USD
- Market cap: 7643433492.8 USD
- Last updated: 2026-08-05
## Business Overview
### Cortisol Modulation Platform
Corcept Therapeutics develops medicines that selectively modulate the glucocorticoid receptor and the effects of cortisol. Its portfolio spans endocrinology, oncology, metabolism and neurology.
### Cushing’s Syndrome Franchise
Corcept has an established commercial business treating hypercortisolism in patients with Cushing’s syndrome. Relacorilant has also completed the pivotal GRACE program, supporting the company’s effort to expand and modernize this endocrine franchise.
### LIFYORLI in Ovarian Cancer
LIFYORLI, or relacorilant, is FDA approved with nab-paclitaxel for platinum-resistant ovarian cancer. The approval establishes Corcept’s first oncology product and validates cortisol modulation as a way to improve response to anticancer therapy.
### Oncology Expansion
The BELLA program is evaluating relacorilant combinations in platinum-resistant and platinum-sensitive ovarian cancer and in previously treated endometrial cancer. These studies are intended to broaden use across gynecologic malignancies and treatment settings.
### Metabolic and Neurologic Pipeline
Miricorilant is in the Phase 2b MONARCH trial for metabolic dysfunction-associated steatohepatitis. Dazucorilant is being prepared for Phase 3 testing in amyotrophic lateral sclerosis following a survival signal in the Phase 2 DAZALS study.
## Why The Stock Is Moving

As of Aug 5, 2026, CORT closed up 0.81% at $110.69. No new same-company headline was identified in the current news window.

## Future Catalysts

- European decision on relacorilant plus nab-paclitaxel for platinum-resistant ovarian cancer expected by year-end 2026.
- BELLA Part A results expected by year-end 2026.
- Phase 2b MONARCH results for miricorilant in MASH expected by year-end 2026.
- Initiation of a Phase 3 dazucorilant trial in ALS planned later in 2026.

## Recent News
- 2026-07-29 20:05 EST — [Corcept Therapeutics Announces Second Quarter Financial Results and Provides Corporate Update](https://biopharmsignal.com/news/CORT/corcept-therapeutics-announces-second-quarter-financial-results-and-provides-cor-8ea3b293) — Source: Corcept
- 2026-07-22 20:05 EST — [Corcept Therapeutics to Announce Second Quarter Financial Results, Provide Corporate Update and Host Conference Call](https://biopharmsignal.com/news/CORT/corcept-therapeutics-to-announce-second-quarter-financial-results-provide-corpor-1db34366) — Source: Corcept
- 2026-06-17 20:28 EST — [Corcept Resubmits New Drug Application for Relacorilant as a Treatment for Patients with Cushing’s Syndrome](https://biopharmsignal.com/news/CORT/corcept-resubmits-new-drug-application-for-relacorilant-as-a-treatment-for-patie-aa5e76db) — Source: Corcept
- 2026-06-06 20:45 EST — [Corcept Presents New Data at ADA: Improved Outcomes in Patients Receiving a GLP-1 with Difficult-to-Control Type 2 Diabetes and Hypercortisolism Treated with Korlym®](https://biopharmsignal.com/news/CORT/corcept-presents-new-data-at-ada-improved-outcomes-in-patients-receiving-a-glp-1-72aa9a5b) — Source: Corcept
- 2026-05-29 20:33 EST — [Corcept Presents New Data at ASCO 2026: Lifyorli™ Overall Survival Across All Subgroups of Patients with Platinum-Resistant Ovarian Cancer, Including Those with Recent Taxane Exposure](https://biopharmsignal.com/news/CORT/corcept-presents-new-data-at-asco-2026-lifyorlitm-overall-survival-across-all-subgroups-of-patients-with-platinum-resistant-ovarian-cancer-including-those-with-recent-taxane-exposure) — Source: Corcept